Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects

Pharmacology, Toxicology and Pharmaceutical Science

• Ginkgo Biloba Extract 100%
• Normal Human 100%
• Midazolam 100%
• Fexofenadine 100%
• Lopinavir 100%
• Pharmacokinetics 100%
• Ritonavir 33%
• Lopinavir Plus Ritonavir 33%
• Proteinase Inhibitor 26%
• CYP3A4 20%
• P-Glycoprotein 13%
• CYP3A 13%
• Liver Enzyme 6%
• Triacylglycerol 6%
• Human Immunodeficiency Virus Proteinase Inhibitor 6%
• Bilirubin 6%

Keyphrases

• Pharmacokinetics 100%
• Ginkgo Biloba Extract 100%
• Midazolam 100%
• Fexofenadine 100%
• Lopinavir 100%
• Cytochrome P450 3A4 (CYP3A4) 20%
• Ritonavir 20%
• Steady State 13%
• Healthy Volunteers 13%
• Protease Inhibitors 13%
• Cytochrome P450 3A (CYP3A) 13%
• Probe Drug 13%
• Ritonavir-boosted Protease Inhibitors 13%
• Cmax 6%
• Metabolism 6%
• Moderate to Severe 6%
• Hepatic Enzymes 6%
• P-glycoprotein (P-gp) 6%
• Single Sequence 6%
• Sequence Design 6%
• HIV Protease Inhibitors 6%
• Unboosted 6%
• Single Oral Dose 6%
• In Vitro Data 6%
• Hepatic Cholesterol 6%
• Hepatic Fat 6%
• P-glycoprotein Activity 6%
• Total Bilirubin 6%
• Laboratory Results 6%